Deployment of Antibody Technologies in Oncology

Published by: BioSeeker Group AB

Published: Apr. 1, 2008 - 163 Pages

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Boxes

4.2 List of Figures

4.3 List of Tables

5 Cancer Antibodies: The Growth Engine of the Pharmaceutical Market

5.1 Where We Stand Today

5.2 The Current Antibody Cancer Pipeline of Big Pharma and Biotech

5.3 Recent Changes in the Competitive Landscape of Monoclonal Antibody Technologies

5.3.1 Big Pharma’s Race for Monoclonal Technologies

5.3.2 The Race to the First Approved Miniature Antibody

5.4 Technology Platform Approaches to Monoclonal Antibody Therapeutics

5.5 Drug Discovery and Development Platforms

6 Monoclonal Antibody Technologies- Protein Engineering and Library Platforms

6.1 From Mouse to Human Mabs

6.2 Human Antibodies from Transgenic Mice

6.3 Library Display Platforms

6.4 Antibodies Blown to Bits: From Full Length to Fragments

7 Classification of Technology Platforms by Monoclonal Antibody Specifics

7.1 Monoclonal Antibody Sources

7.1.1 B cells

7.1.2 Plasma

7.1.3 Cancer Stem Cells and Tumor Tissue

8 Active Immunotherapeutic Platforms Using Monoclonal Antibodies

8.1 Antigen Presenting Cells/Dendritic Cells

8.2 T cells

9 Monoclonal Immuoconjugates: Strategies and Platforms

9.1 Cytotoxin-Conjugated Antibody Platforms

9.2 Radioisotope-Conjugated Antibody Platforms

9.3 Antibody-Linker Platforms

9.4 Vasculature-Targeting Platforms

10 Monoclonal Antibody Expression Platforms

10.1 Mammalian Cell, Bacterial and Hybridoma Platform Technologies

10.2 Plant and Animal Platforms of Antibody Production

10.3 Monoclonal Antibody Processing Platforms

11 Monoclonal Antibody Platforms for Non-Protein Targets

11.1 Monoclonal Antibody Platforms for Carbohydrate

11.2 Monoclonal Antibody Platforms for Lipid

12 Post-Translational Modification Platforms

12.1 Glycosylation modification

13 Novel Strategies for Monoclonal Antibody Delivery

13.1 Gene Delivery and Transfer Technologies

13.2 Epidermal Delivery

14 Monoclonals Based on Non-IgG1 Immunoglobulin Structures

15 Alternative Non-Antibody Protein Binding Technologies

16 Monoclonal Antibody Technology Profiles _(Truncated list)76-

16.1 AbGenomics

16.1.1 AbProt™

18 Cancer Highlights No 8 Vol 7 2008 | BioSeeker Group AB ©

16.98.1 Human Engineering™ Technology HE™ technology

16.98.2 Microbial Expression Technology

18 Technology Platform Index

19 Company Index

4.1 List of Boxes

Box 1: Desirable Immunogenicity from a Murine Antibody

Box 2: mAb Competition for CD200

Box 3: Using mAb Fragments to Bind Intracellular Targets

Box 4: Cancer Stem Cells: A New Paradigm in Cancer Therapeutics

Box 5: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies

4.2 List of Figures

Figure 1: Developmental Status of the Antibody-based Pharmaceutical Pipeline in Oncology

Figure 2: Top 10 Big Pharma Cancer mAb Pipeline

Figure 3: Top 10 Biotech Company Cancer mAb Pipeline

Figure 4: Investigator Country of Origin

Figure 5: Company Breakdown by Platform Classification

4.3 List of Tables

Table 1: Monoclonal Antibody Therapeutics Approved for Cancer Indications

Table 2: Recent Noteworthy Acquisitions and Mergers in the mAb-based Oncology Therapeutic Market

Table 3: TechPlatforms of Investigators Involved in Monoclonal Antibody Therapy of Cancer

Table 4: Selected Companies and their Antibody Species Specificity

Table 5: Pipeline of the Four Investigators with Transgenic Mouse Technology

Table 6: Library Display Platform Technologies

Table 7: Full Size Antibodies vs Antibody Fragments

Table 8: Research Platforms for Cancer Immunotherapy using Antibody Fragments/Formats

Table 9: Developmental Stage of Selected Bispecific Antibodies

Table 10: Developmental Stage of Selected Trispecific Antibodies

Table 11: Human Source Material for Monoclonal Antibody Platforms

Table 12: Monoclonal Antibody Technology Platforms for Immune Cell Activation

Table 13: Monoclonal Antibody Immunoconjugates Aprroved for Cancer Indications

Table 14: Monoclonal Antibody Immunoconjugation Technologies

Table 15: Radioisotope Platforms for mAb Technology

Table 16: Technology Platforms Categorized by mAb-based Expression System

Table 17: Non-Protein Targets of Monoclonal Antibody Platforms

Table 18: Technology Platforms for Post-Translational Modification of Monoclonal Antibodies

Table 19: Technology Platforms Specific for mAb Delivery

Table 20: Company Platforms Based on Non-IgG1 Immunoglobulin Structures

Table 21: Selected Companies with Cancer-Targeting Protein Therapeutics Based on Non-IgG Domains

Abstract

• A single source for market wide competing monoclonal antibody technologies in oncology
• Thorough examination of the leading cancer therapeutic antibody technologies
• The race towards the next generation of therapeutic antibodies
• Competing platforms for expression, delivery, and modification of antibodies

• improve your competitor analysis
• allow you to assess the strengths/weaknesses of competing technologies
• outline R&D alignments
• allow you to assess the direction of future technologies

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.